Related Articles
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild‑type disease during the early disease course
Anticancer immune reactivity and long‑term survival after treatment of metastatic ovarian cancer with dendritic cells
ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines.